Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen:
doi:10.22028/D291-41165
Titel: | Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved trial |
VerfasserIn: | Böhm, Michael Butler, Javed Mahfoud, Felix Filippatos, Gerasimos Ferreira, João Pedro Pocock, Stuart J. Slawik, Jonathan Brueckmann, Martina Linetzky, Bruno Schüler, Elke Wanner, Christoph Zannad, Faiez Packer, Milton Anker, Stefan D. |
Sprache: | Englisch |
Titel: | European Journal of Heart Failure |
Bandnummer: | 24 |
Heft: | 10 |
Seiten: | 1883-1891 |
Verlag/Plattform: | Wiley |
Erscheinungsjahr: | 2022 |
Freie Schlagwörter: | Empagliflozin Heart failure Cardiovascular outcomes Resting heart rate Atrial fibrillation |
DDC-Sachgruppe: | 610 Medizin, Gesundheit |
Dokumenttyp: | Journalartikel / Zeitschriftenartikel |
Abstract: | Aims Empagliflozin reduces cardiovascular death (CVD) or heart failure hospitalization (HHF) in patients with heart failure and preserved ejection fraction (HFpEF). Treatment effects and safety in relation to resting heart rate (RHR) have not been studied. Methods and results The interplay of RHR and empagliflozin effects in EMPEROR-Preserved was evaluated. We grouped patients (n = 5988) according to their baseline RHR (<70 bpm [n = 2650], 70–75 bpm [n = 967], >75 bpm [n = 1736]) and explored the influence of RHR on CVD or HHF (primary outcome) and its components in sinus rhythm or atrial fibrillation/flutter (AF) and adverse events. We studied the efficacy of empagliflozin across the RHR spectrum. Compared to placebo, empagliflozin did not change heart rate over time. The primary outcome (p for trend = 0.0004) and its components CVD (p trend = 0.0002), first HHF (p for trend = 0.0099) and all-cause death (p < 0.0001) increased with RHR only in sinus rhythm but not AF. The risk increase with RHR was similar in patients with heart failure and mildly reduced ejection fraction (left ventricular ejection fraction [LVEF] 40–49%) and HFpEF (LVEF ≥50%). Baseline RHR had no influence on the effect of empagliflozin on the primary outcomes (p for trend = 0.20), first HHF (p for trend = 0.49). There were no clinically relevant differences in adverse events between empagliflozin and placebo across the RHR groups. Conclusion Resting heart rate associates with outcomes only in sinus rhythm but not in AF. Empagliflozin reduced outcomes over the entire RHR spectrum without increase of adverse events. |
DOI der Erstveröffentlichung: | 10.1002/ejhf.2677 |
URL der Erstveröffentlichung: | https://doi.org/10.1002/ejhf.2677 |
Link zu diesem Datensatz: | urn:nbn:de:bsz:291--ds-411651 hdl:20.500.11880/36937 http://dx.doi.org/10.22028/D291-41165 |
ISSN: | 1879-0844 1388-9842 |
Datum des Eintrags: | 24-Nov-2023 |
Bezeichnung des in Beziehung stehenden Objekts: | Supporting Information |
In Beziehung stehendes Objekt: | https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1002%2Fejhf.2677&file=ejhf2677-sup-0001-Supinfo.pdf |
Fakultät: | M - Medizinische Fakultät |
Fachrichtung: | M - Innere Medizin |
Professur: | M - Prof. Dr. Michael Böhm |
Sammlung: | SciDok - Der Wissenschaftsserver der Universität des Saarlandes |
Dateien zu diesem Datensatz:
Datei | Beschreibung | Größe | Format | |
---|---|---|---|---|
European J of Heart Fail - 2022 - B hm - Heart failure outcomes according to heart rate and effects of empagliflozin in.pdf | 962,12 kB | Adobe PDF | Öffnen/Anzeigen |
Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons